TIRAGOLUMAB for Bladder transitional cell carcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 6 adverse event reports in the FDA FAERS database where TIRAGOLUMAB was used for Bladder transitional cell carcinoma.
Most Reported Side Effects for TIRAGOLUMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Off label use | 58 | 10.4% | 10 | 15 |
| Hyperthyroidism | 39 | 7.0% | 2 | 7 |
| Pneumonia | 29 | 5.2% | 12 | 27 |
| Pneumonitis | 26 | 4.7% | 8 | 25 |
| Infusion related reaction | 23 | 4.1% | 13 | 8 |
| Intentional product use issue | 23 | 4.1% | 6 | 1 |
| Death | 21 | 3.8% | 21 | 0 |
| Adrenal insufficiency | 20 | 3.6% | 0 | 11 |
| Troponin increased | 20 | 3.6% | 0 | 20 |
| Colitis | 15 | 2.7% | 2 | 10 |
| Febrile neutropenia | 14 | 2.5% | 1 | 14 |
| Myocarditis | 14 | 2.5% | 0 | 11 |
| Acute kidney injury | 10 | 1.8% | 1 | 10 |
| Immune-mediated lung disease | 10 | 1.8% | 3 | 9 |
| Diarrhoea | 9 | 1.6% | 2 | 8 |
Other Indications for TIRAGOLUMAB
Hepatocellular carcinoma (75)
Non-small cell lung cancer metastatic (53)
Triple negative breast cancer (47)
Non-small cell lung cancer (45)
Oesophageal squamous cell carcinoma metastatic (39)
Oesophageal squamous cell carcinoma (31)
Small cell lung cancer extensive stage (30)
Metastatic neoplasm (24)
Lung cancer metastatic (16)
Squamous cell carcinoma of lung (16)
Other Drugs Used for Bladder transitional cell carcinoma
GEMCITABINE (335)
CISPLATIN (252)
PEMBROLIZUMAB (251)
ATEZOLIZUMAB (195)
CARBOPLATIN (146)
BACILLUS CALMETTE-GUERIN SUBSTRAIN TICE LIVE ANTIGEN (119)
AVELUMAB (104)
DURVALUMAB (88)
NIVOLUMAB (80)
ENFORTUMAB VEDOTIN-EJFV (68)